



Antitope Limited, UK. Announces EpiScreen™ Collaboration with UCB

DATE –Antitope Ltd. today announced a research collaboration with the UCB where Antitope will apply EpiScreen™ technology to profile the immunogenicity of therapeutic monoclonal antibodies.

“We are very pleased to be working with UCB whom we recognize as a world-class company in the development and commercialization of therapeutic antibodies” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. “We look forward to assisting UCB in selecting therapeutic antibodies with a low potential for immunogenicity”

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope’s proprietary EpiScreen™ technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope’s Composite Human Antibody™ and Composite Protein™ technologies deliver novel therapeutic antibodies and proteins with very low immunogenicity potential through the avoidance of T cell epitopes. Antitope is a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit <http://www.antitope.co.uk>.

About UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA (Monheim, Germany) is a member of the UCB Group.

For further information contact:
Dr Neil Butt
Business Development Director

DRAFT

Antitope
Tel: +44 (0)1223 496190
Email: neil.butt@antitope.co.uk

Dr. Ian Weatherhead
Global R&D Communications
UCB
Tel: 0044 (0)1753 447500
Email: r&dcommunications@ucb-group.com

DRAFT